TABLE 1.
| First author | Year | Prospective or retrospective? | NCT number | Consent obtained | Patients with 18F-FCH imaging | Patients with parathyroidectomy | Masked readers | Readers | Pathology correlation | PET/CT or PET/MRI? | Injected dose range (MBq) | Injected dose average (MBq) | Uptake time (min) | Primary HPT only? |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alharbi | 2018 | Retrospective | No | Yes | 66 | 52 | No | 2 | Yes | Both | NR | 150 | 2 & 50 | Yes |
| Amadou | 2019 | Retrospective | No | No | 41 | 23 | No | NR | Yes | PET/CT | NR | 231 | 60 | Yes |
| Bossert | 2019 | Prospective | No | Yes | 34 | 17 | Unclear | 2 | Yes | PET/CT | NR | 3–3.5/kg | 9 & 60 | Yes |
| Broos | 2019 | Prospective | No | Yes | 271 | 139 | Yes | 3 | Yes | PET/CT | NR | 150 | 5 & 60 | Yes |
| Christakis | 2019 | Prospective | No | Yes | 12 | 12 | Yes | 1 | Yes | PET/CT | NR | 300 | 60 & 90 | Yes |
| Fischli | 2017 | Retrospective | No | Yes | 39 | 23 | No | 1 | Yes | PET/CT | IQR 180–149 | 160 | 45 | Yes |
| Grimaldi | 2018 | Prospective | No | No | 27 | 21 | Unclear | NR | Yes | PET/CT | 77–230 | 100 | 30 | Yes |
| Hocevar | 2017 | Retrospective | No | No | 151 | 151 | No | NR | Yes | PET/CT | NR | 100 | 5 & 60 | Yes |
| Huber | 2018 | Retrospective | No | Yes | 26 | 26 | Unclear | NR | Yes | Both | NR | 151 | 45 | No |
| Khafif | 2019 | Prospective | No | Yes | 19 | 19 | No | 2 | Yes | PET/MRI | NR | 93.75 | 16 | Yes |
| Kluijfhout | 2017 | Prospective | No | Yes | 10 | 10 | Yes | 2 | Yes | PET/MRI | 188 ± 26 | 188 | 0* | Yes |
| Kluijfhout | 2016 | Retrospective | No | Yes | 33 | 33 | Unclear | NR | Yes | PET/CT | NR | 2/kg | 30 | No |
| Lezaic | 2014 | Prospective | No | Yes | 24 | 24 | Unclear | 2 | Yes | PET/CT | NR | 100 | 5 & 60 | Yes |
| López-Mora | 2020 | Prospective | No | Yes | 33 | 33 | Unclear | 3 | Yes | PET/CT: digital vs. analog | NR | 0.1/kg | Unclear | Yes |
| Michaud | 2014 | Prospective | No | Yes | 12 | 12 | No | 1 | Yes | PET/CT | NR | 3/kg | 0† | No |
| Piccardo | 2019 | Prospective | No | Yes | 44 | 31 | Unclear | 2 | Yes | PET/CT | NR | 100 | 10 | Yes |
| Quak | 2018 | Prospective | NCT02432599 | Yes | 25 | 24 | Yes | NR | Yes | PET/CT | NR | 1.5/kg | 60 | Yes |
| Thanseer | 2017 | Prospective | No | Yes | 54 | 54 | Unclear | NR | Yes | PET/CT | 150–185 | 150–185 | 10–15 & 60 | Yes |
| Uslu-Beşli | 2020 | Retrospective | No | Yes | 105 | 81 | No | 2 | Yes | PET/CT | 325.1 ± 86.7 | 325.1 | 15 & 45 | No |
| Zajíčková | 2018 | Retrospective | No | Yes | 13 | 13 | Unclear | 2 | Yes | PET/CT | NR | 180 | 30 | Yes |
*
Dynamic imaging for 40 min.
†
Dynamic imaging for 10 min followed by static acquisition.
NCT = National Clinical Trial; HPT = hyperparathyroidism; NR = not reported; IQR = interquartile range.